Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease primarily affecting apocrine gland-rich areas of the body and presenting with painful nodules, abscesses, sinus tracts, and scarring. HS is a multifactorial disease in which genetic and environmental factors play a key role. The primary defect in HS pathophysiology involves follicular occlusion of the folliculopilosebaceous unit, followed by follicular rupture, and immune responses (perifollicular lympho-histiocytic inflammation), finally leading to the development of clinical HS lesions. HS has a destructive impact on the patient’s quality of life, being a very challenging disease. Available treatments are limited, mostly off-label and with high variability in the reported efficacy. Fortunately, a monoclonal antibody against tumor necrosis factor alpha has been recently approved for treatment of moderate to severe HS, offering patients a promising new option. This review focuses on the main features of HS, including epidemiology, clinical aspects, pathogenesis, severity classifications, comorbidities, and currently available treatments.

Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment / Napolitano, M; Megna, Matteo; Timoshchuk, E. A; Patruno, Cataldo; Balato, Nicola; Fabbrocini, Gabriella; Monfrecola, Giuseppe. - In: CLINICAL, COSMETIC AND INVESTIGATIONAL DERMATOLOGY. - ISSN 1178-7015. - 19:10(2017), pp. 105-115. [10.2147/CCID.S111019]

Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment

Napolitano, M;MEGNA, MATTEO;PATRUNO, CATALDO;BALATO, NICOLA;FABBROCINI, GABRIELLA;MONFRECOLA, GIUSEPPE
2017

Abstract

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease primarily affecting apocrine gland-rich areas of the body and presenting with painful nodules, abscesses, sinus tracts, and scarring. HS is a multifactorial disease in which genetic and environmental factors play a key role. The primary defect in HS pathophysiology involves follicular occlusion of the folliculopilosebaceous unit, followed by follicular rupture, and immune responses (perifollicular lympho-histiocytic inflammation), finally leading to the development of clinical HS lesions. HS has a destructive impact on the patient’s quality of life, being a very challenging disease. Available treatments are limited, mostly off-label and with high variability in the reported efficacy. Fortunately, a monoclonal antibody against tumor necrosis factor alpha has been recently approved for treatment of moderate to severe HS, offering patients a promising new option. This review focuses on the main features of HS, including epidemiology, clinical aspects, pathogenesis, severity classifications, comorbidities, and currently available treatments.
2017
Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment / Napolitano, M; Megna, Matteo; Timoshchuk, E. A; Patruno, Cataldo; Balato, Nicola; Fabbrocini, Gabriella; Monfrecola, Giuseppe. - In: CLINICAL, COSMETIC AND INVESTIGATIONAL DERMATOLOGY. - ISSN 1178-7015. - 19:10(2017), pp. 105-115. [10.2147/CCID.S111019]
File in questo prodotto:
File Dimensione Formato  
bjd.16705.pdf

accesso aperto

Descrizione: articolo definitivo
Tipologia: Versione Editoriale (PDF)
Licenza: Dominio pubblico
Dimensione 1.03 MB
Formato Adobe PDF
1.03 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/670501
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 147
  • ???jsp.display-item.citation.isi??? 128
social impact